{"text": "TITLE:\n      Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib\nSUMMARY:\n      P27A study is designed as a randomized phase Ia/Ib trial to evaluate the safety and\n      immunogenicity of the blood stage candidate vaccine P27A against P. falciparum - P27A\n      antigen and associated adjuvant (Alhydrogel or GLA-SE) - in malaria non exposed European\n      volunteers(Switzerland; phase Ia) and malaria exposed African volunteers (Tanzania; phase\n      Ib).\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          -  Phase Ia Inclusion criteria:\n               1. Healthy volunteers aged 18-45 years\n               2. General good health based on history and clinical examination\n               3. Written informed consent obtained before any study procedure\n               4. Female volunteers practicing contraception before and up to 13 weeks after the\n                  last immunisation\n               5. Available to participate in follow-up for the duration of study (34 weeks)\n               6. Reachable by phone during the whole study period\n          -  Phase Ib inclusion criteria\n               1. Healthy male volunteers aged 18-45 years\n               2. General good health based on history and clinical examination\n               3. Written informed consent obtained before any study procedure\n               4. Available to participate in follow-up for the duration of study (34 weeks)\n               5. Reachable by phone during the whole study period\n               6. Having always lived in an area of low malaria transmission\n        Exclusion Criteria:\n          -  Phase Ia Exclusion criteria:\n               1. Positive pregnancy test for females\n               2. Actively breast feeding females\n               3. Previous participation in any malaria vaccine trial\n               4. Symptoms, physical signs or laboratory values suggestive of systemic disorders,\n                  including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency,\n                  psychiatric and other conditions, which could interfere with the interpretation\n                  of the trial results or compromise the health of the volunteers\n               5. Any clinically significant laboratory abnormalities on screened blood samples\n                  beyond the normal range, as defined at the clinical trial site\n               6. Enrolment in any other clinical trial during the whole trial period\n               7. Intake of chronic medication, especially immunosuppressive agents (steroids,\n                  immunomodulating or immunosuppressive drugs) during the 13 weeks preceding the\n                  screening visit or during the trial period except topical and inhaled steroids\n               8. Volunteers unable to be closely followed for social, geographic or psychological\n                  reasons\n               9. Previous history of drug or alcohol abuse interfering with normal social\n                  function during a period of one year prior to enrolment in the study\n              10. Known hypersensitivity to any of the vaccine components (adjuvant or peptide)\n              11. Vaccination or infusion of gammaglobulin from 4 weeks prior to the first\n                  vaccination and up to 6 weeks after the third vaccination\n              12. Any history of malaria\n              13. History of living in a malaria endemic area for more than five (5) years OR\n                  living in a malaria endemic area in early childhood. For practical purposes, all\n                  regions for which malaria chemoprophylaxis is advised by travel clinic are\n                  considered malaria endemic (cf. www.safetravel.ch).\n              14. Known exposure to malaria in the previous six (6) months, defined as a visit to\n                  a malaria endemic region\n              15. P27A ELISA positive OR parasite ELISA antibody positive AND Known exposure to\n                  malaria in a malaria endemic area\n              16. P27A ELISA positive AND parasite ELISA antibody positive (with or without\n                  history of stay in a malaria endemic area)\n              17. Intention to travel to malaria endemic countries during the study period\n              18. Positive HIV, HBV or HCV tests\n          -  Phase Ib exclusion criteria\n               1. Previously participated in any malaria vaccine trial\n               2. Symptoms, physical signs or laboratory values suggestive of systemic disorders,\n                  including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency,\n                  psychiatric and other conditions, which could interfere with the interpretation\n                  of the trial results or compromise the health of the volunteers\n               3. Any clinically significant laboratory abnormalities on screened blood samples\n                  beyond the normal range, as defined at the clinical trial site\n               4. Enrolment in any other clinical trial during the whole trial period\n               5. Intake of chronic medication, especially immunosuppressive agents (steroids,\n                  immunomodulating or immunosuppressive drugs) during the thirteen weeks preceding\n                  the screening visit or during the trial period except topical and inhaled\n                  steroids\n               6. Volunteers unable to be closely followed for social, geographic or psychological\n                  reasons\n               7. Previous history of drug or alcohol abuse interfering with normal social\n                  function during a period of one year prior to enrolment in the study\n               8. Known hypersensitivity to any of the vaccine components (adjuvant or peptide) or\n                  to any of the control vaccine components\n               9. Vaccination OR infusion of gammaglobulins from four (4) weeks prior to the first\n                  vaccination and up to six (6) weeks after the third vaccination\n              10. Previous vaccination with the control vaccine\n              11. Positive HIV, HCV test or HBVsAg positive\n              12. Malaria parasite positivity by microscopy and/or RDT\n              13. Having had a history of confirmed malaria episode in the last five year\n", "cuis": "C0024530 C3541306 C0042196 C0042210 C0229664 C0851353 C1300072 C1706368 C1552616 C1706244 C0947630 C0018792 C0220825 C0042210 C0005768 C0229664 C1300072 C0858318 C0733770 C0063083 C0024530 C0206255 C1744563 C0332157 C0001551 C0599990 C0024530 C0206255 C1744563 C0332157 C0243161 C0013893 C0243161 C0243161 C0031809 C1456356 C3812897 C3891294 C0262926 C2004062 C0514044 C0802641 C0184661 C0025664 C0944777 C0945766 C1948041 C3538935 C3539779 C0449999 C1144702 C0947630 C0700589 C0344221 C0493327 C0877698 C0086286 C0086580 C0020971 C0042196 C0302020 C0848563 C0042200 C0199804 C0199808 C0199810 C0849707 C0850113 C0948201 C1656594 C0947630 C0332534 C0720099 C2926735 C0025344 C0947630 C0243161 C0031809 C1456356 C3812897 C3891294 C0262926 C2004062 C0514044 C0802641 C0184661 C0025664 C0944777 C0945766 C1948041 C3538935 C3539779 C0449999 C1144702 C0947630 C0947630 C0332534 C0720099 C2926735 C0025344 C0947630 C0024530 C0206255 C1744563 C1550472 C0242781 C0332579 C0243161 C0243161 C0240802 C0430066 C0151865 C0006147 C1623040 C1623041 C0420983 C0438100 C0558161 C0206255 C0018792 C0311392 C0012634 C0007222 C0017178 C1457887 C3854129 C1706867 C0022885 C1571737 C2598148 C0021051 C1855166 C0043194 C0221026 C0549463 C1279481 C3714976 C3887460 C0007220 C0436125 C0497234 C0024109 C2707265 C0205054 C0022646 C0459471 C3173575 C0438154 C0456377 C0012634 C1548428 C3526598 C2945640 C0018792 C0178913 C3809765 C0015393 C0151583 C0151611 C0476403 C0522214 C1832603 C2183966 C2674738 C0022885 C1571737 C2598148 C1096775 C1553386 C2702329 C1096775 C0025344 C0018792 C0021081 C0496526 C0013227 C2081612 C2094204 C0033045 C1971835 C0802604 C2598133 C3251814 C0021081 C0021079 C0021080 C0013227 C0678889 C2065041 C0586793 C0199230 C0220908 C1409616 C1698960 C1710031 C0025344 C1512346 C0018792 C1306597 C0848372 C1299582 C1553382 C2697660 C0085762 C0262926 C2004062 C1553386 C0013227 C1254351 C0031843 C1705273 C0025344 C0947630 C1561543 C0020517 C0520946 C0441750 C0013182 C0016470 C0037296 C0079840 C0585186 C4062895 C0011432 C0085636 C0151206 C0301925 C0577628 C0949570 C1405033 C0042210 C0001551 C0202100 C0030953 C0291443 C0388060 C0042196 C1114735 C0574032 C0854643 C0042196 C2713304 C0058773 C0419749 C0262926 C2004062 C0024530 C0206255 C1744563 C0262926 C2004062 C0024530 C0206255 C1744563 C0024530 C0206255 C1744563 C0220644 C0282515 C0362063 C2939437 C0024530 C0206255 C1744563 C1555670 C0024530 C0206255 C1744563 C0274281 C0332157 C2220266 C0024530 C0206255 C1744563 C1512346 C1561542 C0024530 C0206255 C1744563 C0741132 C0587779 C0587781 C0587790 C0241883 C0587783 C0853878 C0855239 C0919706 C0920548 C0587806 C0274281 C0332157 C2220266 C1550557 C1514241 C0024530 C0206255 C1744563 C0741132 C0587779 C0587781 C0587790 C0241883 C0587783 C0853878 C0855239 C0919706 C0920548 C0587806 C1550557 C1514241 C0262926 C2004062 C0024530 C0206255 C1744563 C0162425 C0024530 C0206255 C1744563 C1555670 C0025344 C0947630 C1514241 C0392366 C3850116 C0243161 C0206255 C0018792 C0311392 C0012634 C0007222 C0017178 C1457887 C3854129 C1706867 C0022885 C1571737 C2598148 C0021051 C1855166 C0043194 C0221026 C0549463 C1279481 C3714976 C3887460 C0007220 C0436125 C0497234 C0024109 C2707265 C0205054 C0022646 C0459471 C3173575 C0438154 C0456377 C0012634 C1548428 C3526598 C2945640 C0018792 C0178913 C3809765 C0015393 C0151583 C0151611 C0476403 C0522214 C1832603 C2183966 C2674738 C0022885 C1571737 C2598148 C1096775 C1553386 C2702329 C1096775 C0025344 C0018792 C0021081 C0496526 C0013227 C2081612 C2094204 C0033045 C1971835 C0802604 C2598133 C3251814 C0021081 C0021079 C0021080 C0013227 C0678889 C0199230 C0220908 C1409616 C1698960 C1710031 C0004048 C0025344 C1512346 C0018792 C1306597 C0848372 C1299582 C1553382 C2697660 C0085762 C0262926 C2004062 C1553386 C0013227 C1254351 C0031843 C1705273 C0025344 C0947630 C1561543 C0020517 C0520946 C0441750 C0013182 C0016470 C0037296 C0079840 C0585186 C4062895 C0011432 C0085636 C0151206 C0301925 C0577628 C0949570 C1405033 C0042210 C0001551 C0202100 C0030953 C0291443 C0388060 C0042210 C0042196 C1114735 C0574032 C0854643 C0042196 C2713304 C0058773 C0419749 C0042196 C2713304 C0058773 C0419749 C0042210 C1514241 C0392366 C0456984 C0026018 C0181839 C0024530 C3541306 C0262926 C2004062 C0024530 C0206255 C1744563 C1561543 ", "concepts": "Malaria, Malaria, Vaccine, Vaccine, Blood, Blood, Stage, And summary, summary study, Atrial, Evaluate vaccine, blood, blood, stage, p.falciparum Alhydrogel, hydrogel, malarias, malaria, malari, exposed, Adjuvant, p antigen malarias, malaria, malari, exposed criteria, Eligibility Criteria criteria Clinical examination, NOS, clinical; examination, General, General, history, history informed consent obtained, Informed consent obtained, Procedure, procedures, Procedure, Procedure, Procedure, Procedure, Procedure, Subprocedure, Ct procedure, study contraception, IUD contraception, CAP contraception, CAP contraception, Contraception;F, Contraception;M immunisations, immunisation, isoimmunisation, HIBimmunisation, flu immunisation, bcg immunisation, DPT immunisation, MMR immunisation, CDT immunisation, ADT immunisation, Alloimmunisation, DTP immunisation study, Induration, Duration, Duration period, study criteria Clinical examination, NOS, clinical; examination, General, General, history, history informed consent obtained, Informed consent obtained, Procedure, procedures, Procedure, Procedure, Procedure, Procedure, Procedure, Subprocedure, Ct procedure, study study, Induration, Duration, Duration period, study malarias, malaria, malari, low, Transmission, livedo Criteria criteria Positive pregnancy test, Sensitive pregnancy test, false positive pregnancy test breast feedings, Breast feeding, Breast feeding, breast feeding stop, H/O: breast feeding, breast feeding pain malaria vaccine, Atrial physical signs, disorders, CV disorders, GI disorders, Symptom, Symptom, B-Symptoms, Laboratory, Laboratory, Laboratory immunodeficiency, No immunodeficiency, Immunodeficiency 2, Immunodeficiency 1, Immunodeficiency 5s, Immunodeficiency 4, Immunodeficiency 14, cardiovascular, cardiovascular drug, cardiovascular exam, Pain;cardiovascular, pulmonary, Pulmonary, hepatic, renal interpretations, Interpretation, ECG interpretation, Test interpretation, condition, Psychiatric, Psychiatric compromise, Atrial blood samples, No abnormalities, abnormalities eye, abnormalities csf, EEG abnormalities, EMG abnormalities, VEP abnormalities, Ekg abnormalities, lip abnormalities, Toe abnormalities, Laboratory, Laboratory, Laboratory clinical trial, normal, Orange clinical trial, period, Atrial Immunosuppressive agent, NOS, Immunosuppressive agents, Medications, medication:, medications:, Premedication, IV medication, Medications, Medications, Intake immunosuppressives, immunosuppression, immunosuppression, drugs, immunomodulation inhaled steroids, inhaled steroids use, screening, Screening, screening, screening, Screening, period, visit, Atrial psychological, psychological tic, unable, Ideographic, Ideographic alcohol abuse, history, history, normal, drug, drug function, Function, period, study, year hypersensitivities, Hypersensitivity, hypersensitivity types, hypersensitivity; drug, food hypersensitivity, hypersensitivity tests, milk hypersensitivity, Skin hypersensitivity, Oral hypersensitivity, Tooth hypersensitivity, Light hypersensitivity, Scalp hypersensitivity, Other hypersensitivity, latex hypersensitivity, wheat hypersensitivity, pain; hypersensitivity, vaccine, Adjuvant, C-peptide, peptide t, peptide Q, peptide A Vaccination, Vaccination AE, infusion, Reinfusion vaccination, Revaccinations, DT vaccination, vaccination dt history, history, malarias, malaria, malari History, History, malarias, malaria, malari malarias, malaria, malari, childhood HD Chemoprophylaxis, [V]Chemoprophylaxis, Chemoprophylaxis, malarias, malaria, malari, travel malarias, malaria, malari Exposure, Exposure, exposure, malarias, malaria, malari, visit, month malarias, malaria, malari antibody positive, Ro antibody positive, La antibody positive, Sm antibody positive, EBV antibody positive, RNP antibody positive, Autoantibody positive, DNA antibody positive, CMV antibody positive, HIV antibody positive, Jo-1 antibody positive, Exposure, Exposure, exposure, and, Positive malarias, malaria, malari antibody positive, Ro antibody positive, La antibody positive, Sm antibody positive, EBV antibody positive, RNP antibody positive, Autoantibody positive, DNA antibody positive, CMV antibody positive, HIV antibody positive, Jo-1 antibody positive, and, Positive history, history, malarias, malaria, malari Intention, malarias, malaria, malari, travel, period, study Positive, tests, Etests criteria malaria vaccine, Atrial physical signs, disorders, CV disorders, GI disorders, Symptom, Symptom, B-Symptoms, Laboratory, Laboratory, Laboratory immunodeficiency, No immunodeficiency, Immunodeficiency 2, Immunodeficiency 1, Immunodeficiency 5s, Immunodeficiency 4, Immunodeficiency 14, cardiovascular, cardiovascular drug, cardiovascular exam, Pain;cardiovascular, pulmonary, Pulmonary, hepatic, renal interpretations, Interpretation, ECG interpretation, Test interpretation, condition, Psychiatric, Psychiatric compromise, Atrial blood samples, No abnormalities, abnormalities eye, abnormalities csf, EEG abnormalities, EMG abnormalities, VEP abnormalities, Ekg abnormalities, lip abnormalities, Toe abnormalities, Laboratory, Laboratory, Laboratory clinical trial, normal, Orange clinical trial, period, Atrial Immunosuppressive agent, NOS, Immunosuppressive agents, Medications, medication:, medications:, Premedication, IV medication, Medications, Medications, Intake immunosuppressives, immunosuppression, immunosuppression, drugs, immunomodulation screening, Screening, screening, screening, Screening, inhaled, period, visit, Atrial psychological, psychological tic, unable, Ideographic, Ideographic alcohol abuse, history, history, normal, drug, drug function, Function, period, study, year hypersensitivities, Hypersensitivity, hypersensitivity types, hypersensitivity; drug, food hypersensitivity, hypersensitivity tests, milk hypersensitivity, Skin hypersensitivity, Oral hypersensitivity, Tooth hypersensitivity, Light hypersensitivity, Scalp hypersensitivity, Other hypersensitivity, latex hypersensitivity, wheat hypersensitivity, pain; hypersensitivity, vaccine, Adjuvant, C-peptide, peptide t, peptide Q, peptide A vaccine Vaccination, Vaccination AE, infusion, Reinfusion vaccination, Revaccinations, DT vaccination, vaccination dt vaccination, Revaccinations, DT vaccination, vaccination dt, vaccine Positive, test, test microscopy, microscope, Malaria, Malaria history, history, malarias, malaria, malari, year "}
